Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

100848

registered interest
date	24/10/2014
answering body	Cabinet Office
answering dept id	53
answering dept short name	Cabinet Office
answering dept sort name	Cabinet Office
hansard heading	Electronic Government
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Minister for the Cabinet Office, whether he has received representations on a public sector provider of identity assurance during the Gov.uk Verify programme.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	211904
answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>Information on Verify is published at:</p><p><a href="https://www.gov.uk/government/publications/introducing-govuk-verify" target="_blank">https://www.gov.uk/government/publications/introducing-govuk-verify</a><br> <br>GOV.UK Verify provides the first opportunity for people to verify their identity entirely digitally. <br> The service has not yet been launched and is still in public beta. Performance data will be published in due course.</p><p>Government Digital Service has not received representations from public sector providers of identity assurance</p><p> </p> answering member constituency Horsham answering member printed Mr Francis Maude grouped question UIN 211873 211881 question first answered 29/10/2014 17:49:36 answering member 115 label Biography information for Lord Maude of Horsham
tabling member	4124 label Biography information for Chi Onwurah

100850

registered interest
date	24/10/2014
answering body	Cabinet Office
answering dept id	53
answering dept short name	Cabinet Office
answering dept sort name	Cabinet Office
hansard heading	Electronic Government
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Minister for the Cabinet Office, what progress his Department has made in introducing the Government identity assurance programme, Gov.uk Verify; and if he will make a statement.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	211881
answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>Information on Verify is published at:</p><p><a href="https://www.gov.uk/government/publications/introducing-govuk-verify" target="_blank">https://www.gov.uk/government/publications/introducing-govuk-verify</a><br> <br>GOV.UK Verify provides the first opportunity for people to verify their identity entirely digitally. <br> The service has not yet been launched and is still in public beta. Performance data will be published in due course.</p><p>Government Digital Service has not received representations from public sector providers of identity assurance</p><p> </p> answering member constituency Horsham answering member printed Mr Francis Maude grouped question UIN 211873 211904 question first answered 29/10/2014 17:49:36 answering member 115 label Biography information for Lord Maude of Horsham
tabling member	4124 label Biography information for Chi Onwurah

100852

registered interest
date	24/10/2014
answering body	Cabinet Office
answering dept id	53
answering dept short name	Cabinet Office
answering dept sort name	Cabinet Office
hansard heading	Electronic Government
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Minister for the Cabinet Office, how many (a) successful and (b) unsuccessful registrations of identity there have been through the Gov.uk Verify programme.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	211873
answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>Information on Verify is published at:</p><p><a href="https://www.gov.uk/government/publications/introducing-govuk-verify" target="_blank">https://www.gov.uk/government/publications/introducing-govuk-verify</a><br> <br>GOV.UK Verify provides the first opportunity for people to verify their identity entirely digitally. <br> The service has not yet been launched and is still in public beta. Performance data will be published in due course.</p><p>Government Digital Service has not received representations from public sector providers of identity assurance</p><p> </p> answering member constituency Horsham answering member printed Mr Francis Maude grouped question UIN 211881 211904 question first answered 29/10/2014 17:49:36 answering member 115 label Biography information for Lord Maude of Horsham
tabling member	4124 label Biography information for Chi Onwurah

100876

registered interest
date	24/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Asthma: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how much has been spent on the prescription of asthma drugs in the NHS in each of the last five years.
tabling member constituency	Leicester West
tabling member printed	Liz Kendall
uin	211846
answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>Information on National Health Service expenditure on drugs for the treatment of asthma in primary and secondary care is in the table.</p><p> </p><p><strong> </strong></p><p> </p><p>Drugs for the treatment of osteoporosis have been defined as those included in the following British National Formulary sections:</p><p> </p><p>3.1.1 Adrenoceptor agonists</p><p> </p><p>3.1.2 Antimuscarinic bronchodilators</p><p> </p><p>3.1.3 Theophylline</p><p> </p><p>3.2 Corticosteroids</p><p> </p><p>3.3.1 Cromoglicate and related therapy</p><p> </p><p>3.3.2 Leukotriene receptor antagonists</p><p> </p><p>3.4.2 Allergen immunotherapy (omalizumab only)</p><p> </p><p> </p><p> </p><table><tbody><tr><td colspan="11"><p>Cost of drugs for the treatment of asthma, England<sup>1</sup></p></td></tr><tr><td rowspan="2"><p>Drug name</p></td><td colspan="5"><p>Primary Care (£ millions)</p></td><td colspan="5"><p>Secondary Care (£ millions)</p></td></tr><tr><td><p>2009</p></td><td><p>2010</p></td><td><p>2011</p></td><td><p>2012</p></td><td><p>2013</p></td><td><p>2009</p></td><td><p>2010</p></td><td><p>2011</p></td><td><p>2012</p></td><td><p>2013</p></td></tr><tr><td><p>Aclidinium Bromide</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>0.02</p></td><td><p>1.62</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>0.00</p></td><td><p>0.03</p></td></tr><tr><td><p>Aminophylline</p></td><td><p>1.25</p></td><td><p>1.18</p></td><td><p>1.12</p></td><td><p>1.08</p></td><td><p>1.05</p></td><td><p>0.30</p></td><td><p>0.29</p></td><td><p>0.21</p></td><td><p>0.23</p></td><td><p>0.22</p></td></tr><tr><td><p>Beclometasone Dipropionate</p></td><td><p>84.26</p></td><td><p>87.72</p></td><td><p>90.30</p></td><td><p>97.56</p></td><td><p>102.39</p></td><td><p>1.62</p></td><td><p>1.53</p></td><td><p>1.41</p></td><td><p>1.49</p></td><td><p>1.42</p></td></tr><tr><td><p>Budesonide</p></td><td><p>140.35</p></td><td><p>149.03</p></td><td><p>158.82</p></td><td><p>169.14</p></td><td><p>177.00</p></td><td><p>1.29</p></td><td><p>1.14</p></td><td><p>1.14</p></td><td><p>1.27</p></td><td><p>1.41</p></td></tr><tr><td><p>Budesonide/ Formoterol</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>2.75</p></td><td><p>2.94</p></td><td><p>2.89</p></td><td><p>3.10</p></td><td><p>3.29</p></td></tr><tr><td><p>Ciclesonide</p></td><td><p>0.84</p></td><td><p>0.95</p></td><td><p>1.03</p></td><td><p>1.12</p></td><td><p>1.25</p></td><td><p>0.01</p></td><td><p>0.02</p></td><td><p>0.02</p></td><td><p>0.02</p></td><td><p>0.03</p></td></tr><tr><td><p>Fluticasone</p></td><td><p>366.24</p></td><td><p>380.56</p></td><td><p>387.89</p></td><td><p>392.95</p></td><td><p>396.10</p></td><td><p>1.00</p></td><td><p>0.93</p></td><td><p>0.91</p></td><td><p>1.00</p></td><td><p>0.99</p></td></tr><tr><td><p>Fluticasone/ Salmeterol</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>11.46</p></td><td><p>11.56</p></td><td><p>10.69</p></td><td><p>10.82</p></td><td><p>10.48</p></td></tr><tr><td><p>Formoterol Fumarate</p></td><td><p>5.18</p></td><td><p>4.87</p></td><td><p>4.68</p></td><td><p>4.85</p></td><td><p>4.93</p></td><td><p>0.10</p></td><td><p>0.08</p></td><td><p>0.07</p></td><td><p>0.06</p></td><td><p>0.06</p></td></tr><tr><td><p>Glycopyrronium Bromide</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>0.01</p></td><td><p>2.30</p></td><td><p>0.58</p></td><td><p>0.62</p></td><td><p>0.70</p></td><td><p>0.79</p></td><td><p>1.00</p></td></tr><tr><td><p>Indacaterol Maleate</p></td><td><p>-</p></td><td><p>0.04</p></td><td><p>0.30</p></td><td><p>0.92</p></td><td><p>1.47</p></td><td><p>-</p></td><td><p>0.00</p></td><td><p>0.00</p></td><td><p>0.02</p></td><td><p>0.04</p></td></tr><tr><td><p>Ipratropium Bromide</p></td><td><p>16.15</p></td><td><p>15.02</p></td><td><p>13.74</p></td><td><p>10.32</p></td><td><p>8.61</p></td><td><p>2.74</p></td><td><p>2.84</p></td><td><p>2.59</p></td><td><p>2.65</p></td><td><p>2.70</p></td></tr><tr><td><p>Mometasone Furoate</p></td><td><p>0.36</p></td><td><p>0.31</p></td><td><p>0.26</p></td><td><p>0.23</p></td><td><p>0.21</p></td><td><p>0.76</p></td><td><p>0.71</p></td><td><p>0.61</p></td><td><p>0.63</p></td><td><p>0.67</p></td></tr><tr><td><p>Montelukast</p></td><td><p>38.91</p></td><td><p>43.01</p></td><td><p>46.96</p></td><td><p>51.71</p></td><td><p>31.31</p></td><td><p>0.98</p></td><td><p>1.02</p></td><td><p>1.03</p></td><td><p>1.16</p></td><td><p>0.81</p></td></tr><tr><td><p>Omalizumab</p></td><td><p>0.00</p></td><td><p>0.01</p></td><td><p>0.03</p></td><td><p>0.15</p></td><td><p>0.12</p></td><td><p>5.97</p></td><td><p>9.22</p></td><td><p>12.16</p></td><td><p>14.65</p></td><td><p>17.86</p></td></tr><tr><td><p>Salbutamol</p></td><td><p>83.15</p></td><td><p>82.64</p></td><td><p>60.58</p></td><td><p>60.37</p></td><td><p>59.95</p></td><td><p>3.78</p></td><td><p>3.77</p></td><td><p>3.36</p></td><td><p>3.38</p></td><td><p>3.29</p></td></tr><tr><td><p>Salmeterol</p></td><td><p>48.80</p></td><td><p>45.16</p></td><td><p>41.87</p></td><td><p>36.72</p></td><td><p>34.04</p></td><td><p>0.87</p></td><td><p>0.74</p></td><td><p>0.59</p></td><td><p>0.53</p></td><td><p>0.47</p></td></tr><tr><td><p>Terbutaline Sulphate</p></td><td><p>8.61</p></td><td><p>8.20</p></td><td><p>7.61</p></td><td><p>7.43</p></td><td><p>7.18</p></td><td><p>0.18</p></td><td><p>0.16</p></td><td><p>0.14</p></td><td><p>0.14</p></td><td><p>0.15</p></td></tr><tr><td><p>Theophylline</p></td><td><p>2.18</p></td><td><p>2.17</p></td><td><p>2.15</p></td><td><p>2.22</p></td><td><p>2.26</p></td><td><p>0.12</p></td><td><p>0.11</p></td><td><p>0.11</p></td><td><p>0.11</p></td><td><p>0.11</p></td></tr><tr><td><p>Tiotropium</p></td><td><p>113.61</p></td><td><p>129.98</p></td><td><p>149.81</p></td><td><p>169.35</p></td><td><p>185.24</p></td><td><p>5.69</p></td><td><p>6.03</p></td><td><p>6.22</p></td><td><p>6.64</p></td><td><p>6.87</p></td></tr><tr><td><p>Zafirlukast</p></td><td><p>0.79</p></td><td><p>0.71</p></td><td><p>0.71</p></td><td><p>0.70</p></td><td><p>0.69</p></td><td><p>0.01</p></td><td><p>0.01</p></td><td><p>0.01</p></td><td><p>0.01</p></td><td><p>0.01</p></td></tr><tr><td><p>Other drugs<sup>2</sup></p></td><td><p>0.90</p></td><td><p>0.79</p></td><td><p>0.66</p></td><td><p>0.62</p></td><td><p>0.60</p></td><td><p>0.04</p></td><td><p>0.07</p></td><td><p>0.15</p></td><td><p>0.26</p></td><td><p>0.46</p></td></tr><tr><td><p>Total</p></td><td><p>911.6</p></td><td><p>952.3</p></td><td><p>968.5</p></td><td><p>1,007.5</p></td><td><p>1,018.3</p></td><td><p>40.3</p></td><td><p>43.8</p></td><td><p>45.0</p></td><td><p>49.0</p></td><td><p>52.4</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p><sup>1 </sup>Cost of drugs at NHS list price not taking account of discounts, dispensing costs, fees or prescription charges income. Totals may not add up due to rounding.</p><p> </p><p><sup>2</sup> Other drugs include Azelastine/Fluticasone, Bambuterol Hydrochloride, Beclometasone/ Formoterol, Cromoglicic Acid, Fenoterol Hydrobromide, Fenoterol/Ipratropium Bromide, Fluticasone/ Formoterol, Nedocromil Sodium, Orciprenaline Sulfate and Sodium Cromoglicate.</p><p> </p><p>Source:</p><p> </p><p>Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary care)</p><p> </p><p>Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care)</p><p> </p><p> </p><p> </p><p>Since some drugs are prescribed to treat more than one condition and as the condition for which a drug is prescribed is not collected, it is not possible to separate the different conditions for which a drug may have been prescribed. The information provided may therefore include costs from the prescribing of these drugs for conditions other than for asthma.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2014 17:13:01 answering member 4020 label Biography information for George Freeman
tabling member	4026 label Biography information for Liz Kendall

100881

registered interest
date	24/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ebola
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to his contribution of 13 October 2014, Official Report, column 30, on bed capacity for dealing with potential Ebola patients, how many additional beds will be made available; and at which hospitals they will be made available.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	211872
answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The National Health Service has two ‘Trexler’ beds on stand-by 24 hours a day at the Royal Free Hospital in London, available for use within six hours maximum to allow staff to be mobilised. If needed further beds at the Royal Free Hospital, Newcastle Royal Victoria Infirmary, Royal Liverpool and Broadgreen University Hospital and Sheffield Teaching Hospital would be made available, totalling 12 beds.</p><p> </p><p> </p><p> </p><p>The Department believes this will be sufficient even in the event of an increase in the numbers of cases of Ebola in this country. If there is a significant upscale in numbers further beds could be made available. This would amount to at least 26 beds referenced in the Secretary of State for Health’s statement on 13 October, <em>Official Report, </em>Column 30.</p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 29/10/2014 17:30:23 answering member 3918 label Biography information for Jane Ellison
tabling member	4036 label Biography information for Luciana Berger

100882

registered interest
date	24/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cervical Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what his policy is on the retention of cervical cancer indicators in the Quality and Outcomes Framework.
tabling member constituency	Basildon and Billericay
tabling member printed	Mr John Baron
uin	211899
answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>National Institute for Health and Care Excellence’s independent advisory committee recommends new indicators or changes to existing indicators. NHS Employers, on behalf of NHS England, then negotiate with the General Practitioners Committee of the British Medical Association on which of the published indicators should be applied nationally and what the financial value and payment thresholds for those indicators should be.</p><p> </p><p> </p><p> </p><p>There are currently four indicators within the Quality and Outcomes Framework (QOF) that relate to cervical screening. These have had a positive impact upon increasing the participation in the screening programme in the past years. In April this year, one indicator on cervical screening: <em>The contractor ensures there is a system for informing all women of the results of cervical screening tests</em> was retired, as part of efforts to reduce QOF by more than a third to free up space for GPs to provide more personalised care. Indicators were retired where they were duplicating other existing incentives, were of low clinical value, were unnecessarily prescriptive or were already embedded in clinical practice. The removal of the indicators will reduce bureaucracy, unnecessary patient testing and unnecessary frequency of patient recall and recording.</p><p> </p><p> </p><p> </p><p>There are two indicators that are relevant for all cancers. Indicators on Breast and Bowel Cancer are not currently within the QOF; however Public Health England will continue to explore with NICE whether these conditions should be included.</p><p> </p><p> </p><p>For 2015-16, there will not be any alterations to the cervical screening or cancer indicators, nor any new indicators for cancer, including breast and bowel cancer.</p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 211903 question first answered 29/10/2014 17:20:41 answering member 3918 label Biography information for Jane Ellison
tabling member	1390 label Biography information for Mr John Baron

100883

registered interest
date	24/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hospitals: Greater London
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many times the Parliamentary Under-Secretary of State for Public Health has visited (a) Chelsea and Westminster Hospital, (b) Royal Brompton Hospital, (c) King's College Hospital and (d) St Thomas's Hospital in her ministerial capacity.
tabling member constituency	Copeland
tabling member printed	Mr Jamie Reed
uin	211900
answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>Since September 2012 I have visited:</p><p> </p><p> </p><p> </p><p>23 December 2013, St Thomas’s hospital</p><p> </p><p> </p><p> </p><p>6 March 2014, Kings College hospital</p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 29/10/2014 17:28:08 answering member 3918 label Biography information for Jane Ellison
tabling member	1503 label Biography information for Mr Jamie Reed

100889

registered interest
date	24/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what his policy is on the inclusion of (a) breast and (b) bowel cancer indicators in the Quality and Outcomes Framework.
tabling member constituency	Basildon and Billericay
tabling member printed	Mr John Baron
uin	211903
answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>National Institute for Health and Care Excellence’s independent advisory committee recommends new indicators or changes to existing indicators. NHS Employers, on behalf of NHS England, then negotiate with the General Practitioners Committee of the British Medical Association on which of the published indicators should be applied nationally and what the financial value and payment thresholds for those indicators should be.</p><p> </p><p> </p><p> </p><p>There are currently four indicators within the Quality and Outcomes Framework (QOF) that relate to cervical screening. These have had a positive impact upon increasing the participation in the screening programme in the past years. In April this year, one indicator on cervical screening: <em>The contractor ensures there is a system for informing all women of the results of cervical screening tests</em> was retired, as part of efforts to reduce QOF by more than a third to free up space for GPs to provide more personalised care. Indicators were retired where they were duplicating other existing incentives, were of low clinical value, were unnecessarily prescriptive or were already embedded in clinical practice. The removal of the indicators will reduce bureaucracy, unnecessary patient testing and unnecessary frequency of patient recall and recording.</p><p> </p><p> </p><p> </p><p>There are two indicators that are relevant for all cancers. Indicators on Breast and Bowel Cancer are not currently within the QOF; however Public Health England will continue to explore with NICE whether these conditions should be included.</p><p> </p><p> </p><p>For 2015-16, there will not be any alterations to the cervical screening or cancer indicators, nor any new indicators for cancer, including breast and bowel cancer.</p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 211899 question first answered 29/10/2014 17:20:41 answering member 3918 label Biography information for Jane Ellison
tabling member	1390 label Biography information for Mr John Baron

100898

registered interest
date	24/10/2014
answering body	Department for International Development
answering dept id	20
answering dept short name	International Development
answering dept sort name	International Development
hansard heading	Developing Countries: Disease Control
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for International Development, what assessment she has made of the value of the European and Developing Countries Clinical Trials Partnership as a mechanism for co-ordinating research into (a) a new tuberculosis vaccine and (b) paediatric formulations for antiretroviral treatment.
tabling member constituency	Foyle
tabling member printed	Mark Durkan
uin	211854
answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The European and Developing Countries Clinical Trials Partnership (EDCTP) provides an effective coordination mechanism for clinical research. Member States provide funding which is matched by the European Commission, and funding is also provided from third parties (e.g. philanthropic foundations and the private sector). .</p><p> </p><p> </p><p> </p><p>EDCTP has played an important role in research into a new tuberculosis (TB) vaccine, by increasing the amount of TB vaccine trial activity in countries with a high burden of TB. This includes capacity building and developing sustainable infrastructures which will facilitate TB vaccine trials in the future, as new products emerge. EDTCP has also helped to improve paediatric formulations of antiretroviral treatment (ART). The findings from EDCTP-funded research were used by WHO to develop treatment guidelines for children. This resulted in the first fixed-dose combination antiretroviral drug being made available for a large number of HIV-infected children.</p><p> </p> answering member constituency New Forest West answering member printed Mr Desmond Swayne question first answered 29/10/2014 17:49:17 answering member 55 label Biography information for Sir Desmond Swayne
tabling member	1594 label Biography information for Mark Durkan

100901

registered interest
date	24/10/2014
answering body	Department for International Development
answering dept id	20
answering dept short name	International Development
answering dept sort name	International Development
hansard heading	Developing Countries: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for International Development, if she will support the inclusion of a reference to universal health coverage in the Health Goal in the Sustainable Development Goals.
tabling member constituency	East Renfrewshire
tabling member printed	Mr Jim Murphy
uin	211844
answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The UK government welcomed the emphasis on Universal Health Coverage in the report of the High-Level Panel, chaired by the Prime Minister, and was pleased to see its inclusion as a target in the proposal of the Open Working Group for Sustainable Development Goals.</p><p> </p> answering member constituency Putney answering member printed Justine Greening question first answered 29/10/2014 17:15:36 answering member 1555 label Biography information for Justine Greening
tabling member	595 label Biography information for Mr Jim Murphy